Key Insights

Highlights

Treatment Research

2 treatments under study, led by Obeticholic Acid

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

100.0%

1 terminated out of 1 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

1Total
Phase 2/3 (1)

Trial Status

Terminated1

Clinical Trials (1)

Showing 1 of 1 trials
NCT06121375Phase 2/3Terminated

Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Obeticholic Acid (OCA) Compared to Placebo in Pediatric Participants With Biliary Atresia, Post-hepatoportoenterostomy

Showing all 1 trials

Research Network

Common Treatments

  • Obeticholic Acid1
  • Oca1

Active Sponsors

  • Intercept Pharmaceuticals1
  • Intercept Pharmaceuticals Inc.1

Top Investigators

Related Conditions

  • Biliary Atresia1

Activity Timeline